Synageva BioPharma Corp. took advantage of a 2 percent increase in its stock price during the New Year and bumped up the number of shares to boost the size of its public offering by 25 percent, from approximately 1.7 million shares cited in a preliminary prospectus supplement filed Thursday with the SEC to 2.15 million shares at Thursday's closing price of $47.53.
Labrys Biologics Inc. burst on the biotech scene with a $31 million Series A, a new president and CEO and the acquisition of a Phase II-ready anti-calcitonin gene-related peptide (CGRP) humanized monoclonal antibody (MAb) from Pfizer Inc. to treat chronic migraine.
AlphaCore Pharma Inc. has maintained a low profile since its founding in 2007, perhaps befitting for a biotech working in the rare orphan indication of familial LCAT deficiency (FLD).
In less than three years, privately held Immune Pharmaceuticals has matured from a start-up launched with a single monoclonal antibody (MAb) licensed from Canada's iCo Therapeutics Inc. into a biotech capable of absorbing the assets of publicly traded EpiCept Corp. in an all-stock deal.
John Steel is running for his life. Diagnosed with Type I diabetes 30 years ago, the president and CEO of Islet Sciences Inc. endures a daily regimen of insulin injections and glucose monitoring.
HealthCare Royalty Partners II LP closed an $80 million financing with privately held Nuron Biotech Inc. that included a $30 million equity investment and a $50 million synthetic royalty agreement linked to future sales of Meningitec, a vaccine Nuron acquired earlier this month from Pfizer Inc., and its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]).
As promised in February when Cempra Inc. completed its initial public offering (IPO), the Chapel Hill, N.C.-based biotech initiated its global Phase III trial of oral solithromycin (CEM-101), a first-in-class fluoroketolide antibiotic candidate, in patients with community-acquired bacterial pneumonia (CABP).
Less than a year after the acquisition of Alvos Therapeutics Inc. gave Arrowhead Research Corp. a library of 42,000 individual targeting sequences, the company has attracted a second research collaboration and license deal.
Four months after raising $76.85 million in an underwritten public offering, Infinity Pharmaceuticals Inc. went back for a heaping plate of seconds, seeking to raise $150 million by pricing an offering of 5.7 million shares of common stock at $26.33 apiece.
